Capricor Therapeutics, Inc. (CAPR)

Market Cap	557.18M
Revenue (ttm)	17.36M
Net Income (ttm)	-55.06M
Shares Out	45.71M
EPS (ttm)	-1.42
PE Ratio	n/a
Forward PE	45.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,559,013
Open	12.12
Previous Close	n/a
Day's Range	11.57 - 13.51
52-Week Range	3.52 - 23.40
Beta	0.85
Analysts	Strong Buy
Price Target	40.14 (+229.29%)
Earnings Date	Aug 6, 2025

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 160
• Stock Exchange: NASDAQ
• Ticker Symbol: CAPR
• Website: https://www.capricor.com

Financial Performance

In 2024, Capricor Therapeutics's revenue was $22.27 million, a decrease of -11.55% compared to the previous year's $25.18 million. Losses were -$40.47 million, 81.6% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price forecast is $40.14, which is an increase of 229.29% from the latest price.

Price Target

$40.14

(229.29% upside)

Analyst Consensus: Strong Buy